
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
3
One Clinical: Working Together to Advance Trial Collaboration
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5